Regeneron Pharmaceuticals (REGN) to Release Quarterly Earnings on Tuesday

Regeneron Pharmaceuticals (NASDAQ:REGN) is projected to announce its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect the company to announce earnings of $9.73 per share and revenue of $3.5712 billion for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $11.56 EPS. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $577.95 on Friday. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $61.26 billion, a price-to-earnings ratio of 14.57, a P/E/G ratio of 1.80 and a beta of 0.31. The firm’s 50 day simple moving average is $576.32 and its 200 day simple moving average is $562.62. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $943.83.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. raised its stake in Regeneron Pharmaceuticals by 3.0% during the second quarter. Geneos Wealth Management Inc. now owns 780 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 23 shares during the last quarter. Evergreen Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 109.6% during the second quarter. Evergreen Capital Management LLC now owns 8,134 shares of the biopharmaceutical company’s stock worth $4,270,000 after buying an additional 4,253 shares during the last quarter. MUFG Securities EMEA plc bought a new position in Regeneron Pharmaceuticals during the second quarter worth $161,000. Howland Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 19.1% during the second quarter. Howland Capital Management LLC now owns 31,795 shares of the biopharmaceutical company’s stock worth $16,692,000 after buying an additional 5,107 shares during the last quarter. Finally, Fairfield Bush & CO. raised its stake in Regeneron Pharmaceuticals by 1.4% during the second quarter. Fairfield Bush & CO. now owns 2,187 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 30 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on REGN shares. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Argus downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Finally, UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $802.35.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.